ESC 365 - Are perceived or calculated bleeding risk related to dapt choice in patients undergoing percutaneous coronary intervention?

ESC Premium Access

Are perceived or calculated bleeding risk related to dapt choice in patients undergoing percutaneous coronary intervention?

Session: Safety issues with anti-platelets drugs

Topic: Antiplatelet Drugs

Speaker: Doctor M. Ferlini (Pavia, IT)

Event: ESC Congress 2018

Congress Presentation

About the speaker

Doctor Marco Ferlini

Foundation IRCCS Policlinic San Matteo - University of Pavia, Pavia (Italy)

0 follower

3 more presentations in this session

Perceived or calculated bleeding risk in patients undergoing percutaneous coronary intervention: inside the post-pci prospective registry

Speaker: Doctor M. Ferlini (Pavia, IT)

Platelet inhibition on brand and generic clopidogrel chronic therapy

Speaker: Doctor A. Soliman (Dammam, SA)

Adverse event profiles after brand or generic clopidogrel in the Food and Drug Administration Adverse Event Reporting System (FAERS)

Speaker: Associate Professor V. Serebruany (Baltimore, US)

Access the full session

Safety issues with anti-platelets drugs

Speakers: Doctor M. Ferlini, Doctor M. Ferlini, Doctor A. Soliman, Associate Professor V. Serebruany

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources